MedTrace Logo

Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

NCT06963281 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 285

Last updated 2025-06-06

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.

Conditions

Interventions

DRUG

IBI3020

Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection

Sponsors & Collaborators

  • Fortvita Biologics (USA)Inc.

    collaborator INDUSTRY

  • Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-29
Primary Completion
2027-12-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06963281 on ClinicalTrials.gov